Navigation Links
Boca Pharmacal Receives FDA Approval for Carbinoxamine Oral Solution
Date:2/27/2008

CORAL SPRINGS, Fla., Feb. 27 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pamlab's Palgic(R) Oral Solution (Carbinoxamine Maleate Oral Solution) 4 mg/5mL. The Company plans to launch its product immediately.

Carbinoxamine Maleate Oral Solution 4mg/5mL is indicated to treat seasonal and perennial allergic rhinitis.

"This approval is another example of our commitment to providing affordable drug products to customers and consistent innovation in the pharmaceutical industry," commented Robert J. Edwards Jr., CEO. "At Boca Pharmacal we pride ourselves on our ability to offer lower volume items that may have been overlooked by some of the larger generic companies. Carbinoxamine Maleate Oral Solution is the first of many approvals we expect in 2008. Having filed multiple ANDA applications coupled with our multinational partnerships we expect 2008 to be a very big year."

Founded in 1998 Coral Springs, FL based Boca Pharmacal manufactures, develops and distributes a wide variety of generic drugs.


'/>"/>
SOURCE Boca Pharmacal, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line
2. Mission Pharmacal Congratulates Exemplary Womens Health Researchers
3. IDC receives patent on dual energy imaging technology
4. Kryptiq Customer Receives HIMSS Nicholas E. Davies Award of Excellence
5. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
6. Healthy Start of Southwest Florida Receives Grant From March of Dimes to Assess Needs of Pregnant Women and Babies
7. Bishop T. D. Jakes Receives The Black Aids Institute 2008 Heroes in the Struggle Award
8. Algeta Receives IND Approval for Alpharadin(TM) to Commence Clinical Development in the USA
9. Florida Tissue Services Receives National Accreditation
10. Siemens Receives FDA Approval for the VERSANT 440 Molecular System
11. Global Med Technologies(R), Inc. Receives FDA 510(K) Clearance for ElDorado Donor(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology: